Associated Papers
A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function.
Bencivenga D et al.
Molecular Oncology, 2021
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Costa C et al.
Cancer Discovery, 2020
Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma.
Qiu H et al.
Molecular Carcinogenesis, 2017
Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner.
Armenia J et al.
Oncotarget, 2014
24727437 (PubMed )
Supplement: oncotarget-05-1185-s002.pdf
Fbxl12 triggers G1 arrest by mediating degradation of calmodulin kinase I.
Mallampalli RK et al.
Cellular Signalling, 2013
Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.
Yan Y et al.
Cell Cycle (georgetown, Tex.), 2011
Mutant p27(Kip1) and its potential effect as hepatocellular gene therapy.
Lu M et al.
Archives of Medical Research, 2008
Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway.
Schepers H et al.
Experimental Hematology, 2005
14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1).
Sekimoto T et al.
The Embo Journal, 2004
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Shin I et al.
Nature Medicine, 2002
Select a paper to view details